PE20010904A1 - Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituida - Google Patents

Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituida

Info

Publication number
PE20010904A1
PE20010904A1 PE2000001267A PE0012672000A PE20010904A1 PE 20010904 A1 PE20010904 A1 PE 20010904A1 PE 2000001267 A PE2000001267 A PE 2000001267A PE 0012672000 A PE0012672000 A PE 0012672000A PE 20010904 A1 PE20010904 A1 PE 20010904A1
Authority
PE
Peru
Prior art keywords
trifluoromethyl
ethyl
ethyl ester
quinoline
dihydro
Prior art date
Application number
PE2000001267A
Other languages
English (en)
Inventor
Troy Anthony Appleton
Lyle Robinson Brostom
Douglas John Meldrum Allen
Derek Lawrence Tickner
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20010904A1 publication Critical patent/PE20010904A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

SE REFIERE A LA FORMA CRISTALINA DEL ESTER ETILICO O ETANOLATO DEL ESTER ETILICO DEL ACIDO [2R,4S]-4-[(3,5-BIS-TRIFLUOROMETIL-BENCIL)-METOXICARBONIL-AMINO]-2-ETIL-6-TRIFLUOROMETIL-3,4-DIHIDRO-2H-QUINOLINA-1-CARBOXILICO ANHIDRO QUE SE CARACTERIZA POR SU PATRON DE DIFRACCION DERAYOS X; UTILIZANDOSE DE 0,1 mg/Kg/DIA-10 mg/Kg/DIA. TAMBIEN SE REFIERE A PROCEDIMIENTOS PARA LA PREPARACION QUE COMPRENDE DISOLVER O MEZCLAR EL ESTER ETILICO DEL ACIDO [2R,4S]-4-[(3,5-BIS-TRIFLUOROMETIL-BENCIL)-METOXICARBONIL-AMINO]-2-ETIL-6-TRIFLUOROMETIL-3,4-DIHIDRO-2H-QUINOLINA-1-CARBOXILICO EN HEXANOS A TEMPERATURA AMBIENTE DE 2-24 HORAS. EL COMPUESTO I INHIBE A LA PROTEINA DE TRANSFERENCIA DEL ESTER DE COLESTERILO CETP Y PUEDE SER UTIL PARA EL TRATAMIENTO DE ATEROSCLEROSIS, ENFERMEDAD VASCULAR PERIFERICA, DISLIPIDEMIA, HIPERBETALIPOPROTEINEMIA, HIPOALFALIPOPROTEINEMIA, HIPERTRIGLICERIDEMIA, HIPERCOLESTEROLEMIA
PE2000001267A 1999-11-30 2000-11-28 Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituida PE20010904A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16805199P 1999-11-30 1999-11-30

Publications (1)

Publication Number Publication Date
PE20010904A1 true PE20010904A1 (es) 2001-09-10

Family

ID=22609901

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001267A PE20010904A1 (es) 1999-11-30 2000-11-28 Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituida

Country Status (28)

Country Link
EP (1) EP1246804A1 (es)
JP (1) JP2003515592A (es)
KR (1) KR20020058057A (es)
CN (1) CN1402711A (es)
AP (1) AP2002002531A0 (es)
AU (1) AU1048801A (es)
BG (1) BG106854A (es)
BR (1) BR0015836A (es)
CA (1) CA2392979A1 (es)
CO (1) CO5271716A1 (es)
EA (1) EA200200510A1 (es)
EC (1) ECSP003792A (es)
EE (1) EE200200277A (es)
GT (1) GT200000199A (es)
HU (1) HUP0203521A2 (es)
IL (1) IL149097A0 (es)
IS (1) IS6338A (es)
MA (1) MA26845A1 (es)
MX (1) MXPA02005354A (es)
NO (1) NO20022558L (es)
OA (1) OA12099A (es)
PA (1) PA8506301A1 (es)
PE (1) PE20010904A1 (es)
PL (1) PL355892A1 (es)
TN (1) TNSN00231A1 (es)
TR (1) TR200201446T2 (es)
UY (1) UY26454A1 (es)
WO (1) WO2001040190A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
IL158765A0 (en) 2001-06-21 2004-05-12 Pfizer Prod Inc Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
GT200200170A (es) * 2001-09-28 2003-05-23 Preparacion de inhibidor de cetp anhidro
EP1920766B1 (en) * 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
CN1309370C (zh) * 2002-02-01 2007-04-11 辉瑞产品公司 使用改进的喷雾干燥设备制备均匀喷雾干燥的固体非晶形药物分散体的方法
ES2305434T3 (es) 2002-02-01 2008-11-01 Pfizer Products Inc. Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
SI1533292T1 (sl) 2002-08-30 2007-08-31 Japan Tobacco Inc Dibenzilaminska spojina in njena medicinska uporaba
PL376156A1 (en) 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
JP2006513186A (ja) 2002-12-20 2006-04-20 ファイザー・プロダクツ・インク Ｃｅｔｐ阻害剤およびｈｍｇ−ｃｏａレダクターゼ阻害剤を含む剤形
BRPI0408897A (pt) * 2003-03-28 2006-04-18 Pfizer Prod Inc derivados de 1,2,3,4-tetrahidro-e 1,2-dihidro-quinolina 1,2,4-substituìdos como inibidores de cetp para o tratamento de arteroesclerose e obesidade
MXPA06001417A (es) 2003-08-04 2006-05-15 Pfizer Prod Inc Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas.
DK1670768T3 (da) 2003-10-08 2009-11-09 Lilly Co Eli Forbindelser og fremgangsmåder til at behandle dyslipidæmi
EP1737811B1 (en) * 2004-04-13 2016-08-10 Merck Sharp & Dohme Corp. Cetp inhibitors
JP2008504266A (ja) * 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
WO2006033004A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds as cetp inhibitors
UA90706C2 (ru) 2005-02-24 2010-05-25 Милленниум Фармасьютикалз, Инк. Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
WO2006098394A1 (ja) * 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
AR065670A1 (es) 2007-03-09 2009-06-24 Indigene Pharmaceuticals Inc Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
TWI450896B (zh) 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
MX2017000582A (es) 2014-07-30 2017-04-27 Hoffmann La Roche Marcadores geneticos para predecir la reactividad a terapia con agente que eleva la lipoproteina de alta densidad (hdl) o que imita la lipoproteina de alta densidad (hdl).

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
WO1998033775A1 (en) * 1997-02-03 1998-08-06 American Home Products Corporation 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
TNSN00231A1 (fr) 2002-05-30
JP2003515592A (ja) 2003-05-07
IL149097A0 (en) 2002-11-10
EA200200510A1 (ru) 2002-10-31
EE200200277A (et) 2003-10-15
CO5271716A1 (es) 2003-04-30
EP1246804A1 (en) 2002-10-09
ECSP003792A (es) 2002-04-23
KR20020058057A (ko) 2002-07-12
BG106854A (bg) 2002-12-29
WO2001040190A1 (en) 2001-06-07
AU1048801A (en) 2001-06-12
IS6338A (is) 2002-04-12
NO20022558D0 (no) 2002-05-29
CN1402711A (zh) 2003-03-12
MA26845A1 (fr) 2004-12-20
PA8506301A1 (es) 2002-08-26
UY26454A1 (es) 2001-07-31
CA2392979A1 (en) 2001-06-07
PL355892A1 (en) 2004-05-31
BR0015836A (pt) 2002-08-06
GT200000199A (es) 2002-05-23
TR200201446T2 (tr) 2002-11-21
AP2002002531A0 (en) 2002-06-30
NO20022558L (no) 2002-05-29
OA12099A (en) 2006-05-04
HUP0203521A2 (hu) 2003-02-28
MXPA02005354A (es) 2002-12-11

Similar Documents

Publication Publication Date Title
PE20010904A1 (es) Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituida
KR101514469B1 (ko) 혈관신생 억제제로서 화합물들
SU1015827A3 (ru) Способ получени производных хинолинкарбоновой кислоты или их гидратов
AP2004003059A0 (en) Salt forms of E-2-methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxyl)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
US20030195194A1 (en) Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
CA2676984A1 (en) Compounds for the prevention and treatment of cardiovascular diseases
SK2722003A3 (en) Quinolinone derivatives as tyrosine kinase inhibitors
EP1917245A1 (de) Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
JP2002527434A (ja) キノリン誘導体および抗菌剤としてその使用
AU627285B2 (en) Derivatives of n-phenylbenzamide with anti-ulcer and anti-allergy activity and a method for their preparation
CA2455181A1 (en) Benzimidazo[4,5-f]isoquinolinone derivatives
CN108026045A (zh) 用作RORγ调节剂的经过取代的四氢喹啉酮化合物
CN108602835A (zh) Pde1抑制剂
JPH05503530A (ja) 置換ベンジル成分を含むアンギオテンシン２拮抗物質
JPH09509188A (ja) 新規なピリミジン誘導体およびその製造方法
JPH08176143A (ja) 安定性に優れた８−アルコキシキノロンカルボン酸水和物並びにその製造方法
ES2261496T3 (es) Antagonistas de los canales de calcio de tipo n para el tratamiento del dolor.
Sundriyal et al. Histone lysine methyltransferase structure activity relationships that allow for segregation of G9a inhibition and anti-Plasmodium activity
ES2090081T3 (es) Derivados de indolocarbazol, procedimientos para su obtencion y su empleo.
HUP0300972A2 (hu) Gatifloxacin-pentahidrát
DK0618906T3 (da) Substituerede imidazolderivater og deres fremstilling og anvendelse
ES2038207T3 (es) Procedimiento para la obtencion de 2-piridil-penem-compuestos.
MY109684A (en) Neuroprotective 3, 4-dihydro-2(1h)-quinolone compounds.
CN109400632A (zh) 一种含n-甲基依诺沙星的双-氟喹诺酮基噁二唑脲类衍生物及其制备方法和应用
DE69717969T2 (de) Substituierte n-methyl-n-(4-(piperidin-1-yl)-2-arylbutyl)-benzamide zur behandlung von allergischen erkrankungen

Legal Events

Date Code Title Description
FD Application declared void or lapsed